News Releases

Select year
Categories

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 14, 2025 | Corporate | Financial

Read more

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

May 07, 2025 | Products

Read more

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

May 06, 2025 | Financial

Read more

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Apr 30, 2025 | Products

Read more

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Apr 29, 2025 | Corporate | Financial

Read more

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Apr 25, 2025 | Products

Read more

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Apr 21, 2025 | Products

Read more

Myriad Genetics Announces Inducement Awards

Apr 08, 2025 | Corporate | Financial

Read more

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Apr 07, 2025 | Corporate

Read more

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Feb 27, 2025 | Products

Read more

Myriad Genetics Announces Senior Leadership Transition

Feb 24, 2025 | Corporate | Financial

Read more

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Feb 24, 2025 | Corporate | Financial

Read more

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Feb 24, 2025 | Corporate | Pipeline | Products

Read more

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Feb 19, 2025 | Corporate

Read more

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Feb 18, 2025 | Corporate | Financial

Read more

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Feb 06, 2025 | Products

Read more

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Feb 05, 2025 | Corporate | Pipeline

Read more

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Feb 05, 2025 | Products

Read more

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Jan 29, 2025 | Products

Read more

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Jan 23, 2025 | Products

Read more

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Jan 21, 2025 | Products | Corporate

Read more

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Jan 15, 2025 | Financial | Corporate

Read more

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

Jan 09, 2025 | Products | Corporate

Read more

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 08, 2025 | Corporate | Financial

Read more

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Jan 07, 2025 | Products | Corporate

Read more

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

Jan 06, 2025 | Corporate

Read more